(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.' - 2The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- 3Knesset sets special panel to fast-track Karhi’s communications reform
- 4Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- 5The Main 15 Powerful Business Heads of Today
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Eleven arrested over mass shooting in South Africa tavern
- The Best 20 Photography Instagram Records to Follow
- After harsh winter, Ukrainians find joy in releasing bats rescued from war
- Paraplegic engineer becomes the first wheelchair user to blast into space
- A Couple of Modest Guitars for 2024
- Finding Ideal Date Spots for Two or three Encounters
- Brazil's ex-president Bolsonaro operated on for hernia
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
